121
Participants
Start Date
April 30, 2016
Primary Completion Date
November 30, 2020
Study Completion Date
December 31, 2020
Blood samples for pharmacokinetics exploration
6 blood sample at regular intervals
Imagery
Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
Quality of life scale
Quality of life will be evaluated with questionaries 5 times during the study
Detection of adverse events
The detection will be assessed using the AMA (assistance des malades ambulatoires) system
Saliva samples
Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
Blood sample
A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
Biological statement
"The following parameters will be assessed :~* Complete blood count~* Hemoglobin~* Hepatic enzymes~* Creatinine clearance~* Lactate dehydrogenase rate~* Total bilirubin rate~* Cluster of differentiation 4 T lymphocytes rate~* Total gamma-globulins rate"
Clinical examination
"The clinical examination are composed by :~* Weigh, Height and body mass index measurement~* Clinical state of patient during examination~* Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~* Presence of B symptomatology~* Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
Cancer University Institute of Toulouse Oncopole, Toulouse
University Hospital, Toulouse
OTHER